March 26, 1982

Clinical and Immunologic Effects of Recombinant Leukocyte A Interferon in Eight Patients With Advanced Cancer

Author Affiliations

From the Department of Medicine, Stanford University School of Medicine, Stanford, Calif.

JAMA. 1982;247(12):1718-1722. doi:10.1001/jama.1982.03320370032025

The clinical and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight patients with advanced cancer. Single escalating doses from 3×106 units to 198×106 units were given by intramuscular injection in a phase 1 study. Major toxic effects included pyrexia, fatigue, myalgia, and headache. Data on the effects of IFL-rA on lymphocyte subpopulations and peripheral blood mononuclear-cell surface β2-microglobulin are presented. Four of eight patients had objective tumor regression, indicating that further investigation of this biologically active material is warranted.

(JAMA 1982;247:1718-1722)